Media Center

In the media

The Chinese SciClone becomes shareholder of Ability Pharma with € 2.5 million

Ara

29/12/2020

The Chinese SciClone enters at the biotech Ability Pharma

La Vanguardia

29/12/2020

Ability tests successfully a drug for neuroblastoma

Expansión

17/12/2020

The great leap of a Catalan 'biotech' to cure pancreatic cancer

ARA

09/12/2020

Ability logra financiación de la FDA y abre una ronda en Capital Cell

Expansión

22/10/2020

Ability Pharma capta dos millones de dólares de la FDA para su ensayo clínico de páncreas

Planta Doce

22/10/2020

AbilityPharma capta 5 M€ per a un assaig contra el càncer de pàncreas

ARA

25/03/2020

Ability Pharma receives the acknowledgement from Cerdanyola Empresarial

Parc UAB newsletter

22/11/2019

Ability reinforces the direction and rises 2 million euros from Inveready and Everis

Expansión

13/09/2019

Ability Pharma rises 3.5M€ to finish the clinical trial in cancer

Ara

13/09/2019

A Catalan drug can extend the life expectancy of patients with lung and endometrial cancer

RAC1

06/06/2019

Nine Catalan biotechs among the most promising in Europe

La Vanguardia

28/05/2019

AbilityPharma will start research for cancer in China

El Punt Avui

05/02/2019

The partner of AbilityPharma in China starts clinical trials with the licensed drug

Expansión

04/02/2019

AbilityPharma rises 1.2M euros with the biggest round of Capitall Cell

Ara

10/12/2018

AbilityPharma recibe su tercera designación de medicamento huérfano por la FDA

Expansión

08/11/2018

TechShare, el programa que abre las puertas de la Bolsa a las pymes biotech

Innovaspain

26/09/2018

Cómo facilitar la salida a bolsa de empresas biotecnológicas

Diario Medico

26/09/2018

ABILITY PHARMA COMENÇA LA FASE 2 DEL SEU NOU ANTICANCERIGEN

La Vanguardia

20/09/2018

ABILITYPHARMA ABRE UNA RONDA PARA LUCHAR CONTRA EL CÁNCER

Expansión

13/09/2018

LATEST NEWS

11.05.2021

Press Release

Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as First Line Therapy in Advanced Pancreatic Cancer simultaneously in USA and Europe + info
28.12.2020

Press Release

The Chinese pharmaceutical company SciClone joins the capital of AbilityPharma with an investment commitment of three million dollars + info
16.12.2020

Press Release

The antitumoral drug ABTL0812 shows promising results against neuroblastoma + info
05.11.2020

Press Release

AbilityPharma receives the approval from the FDA and the AEMPS to start the clinical trial of its molecule against pancreatic cancer in the US and Spain + info
22.10.2020

Press Release

AbilityPharma receives a 1.6 million euro grant from the FDA and opens a crowdfunding campaign in Capital Cell + info
22.09.2020

Press Release

ABILITYPHARMA PRESENTS THE RESULTS OF A NEW FIRST-LINE TREATMENT FOR ENDOMETRIAL CANCER + info
09.06.2020

Press Release

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

Press Release

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

Press Release

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG